BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37223851)

  • 1. Simulation of drug-drug interactions between breast cancer chemotherapeutic agents and antiemetic drugs.
    Deb S; Hopefl R
    Daru; 2023 Dec; 31(2):95-105. PubMed ID: 37223851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
    Piechotta V; Adams A; Haque M; Scheckel B; Kreuzberger N; Monsef I; Jordan K; Kuhr K; Skoetz N
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012775. PubMed ID: 34784425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
    Weibel S; Rücker G; Eberhart LH; Pace NL; Hartl HM; Jordan OL; Mayer D; Riemer M; Schaefer MS; Raj D; Backhaus I; Helf A; Schlesinger T; Kienbaum P; Kranke P
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012859. PubMed ID: 33075160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid-induced respiratory depression suspected of drug interaction in a prostate cancer patient: a case report.
    Hamada H; Suzuki E; Endo M; Mihara Y; Iketani S; Ishida M; Miyasato A; Miyazaki K
    Ann Palliat Med; 2024 Mar; 13(2):428-432. PubMed ID: 38584476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-drug interactions with aprepitant in antiemetic prophylaxis for chemotherapy.
    Schoffelen R; Lankheet AG; van Herpen CML; van der Hoeven JJM; Desar IME; Kramers C
    Neth J Med; 2018 Apr; 76(3):109-114. PubMed ID: 29667586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.
    Loos WJ; de Wit R; Freedman SJ; Van Dyck K; Gambale JJ; Li S; Murphy GM; van Noort C; de Bruijn P; Verweij J
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):407-12. PubMed ID: 17051369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and vomiting associated with chemotherapy.
    Rapoport B; Smit T
    Expert Opin Drug Saf; 2017 Jun; 16(6):697-710. PubMed ID: 28460548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
    Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.
    Grunberg SM; Dugan M; Muss H; Wood M; Burdette-Radoux S; Weisberg T; Siebel M
    Support Care Cancer; 2009 May; 17(5):589-94. PubMed ID: 19037667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aprepitant: drug-drug interactions in perspective.
    Aapro MS; Walko CM
    Ann Oncol; 2010 Dec; 21(12):2316-2323. PubMed ID: 20488873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region.
    Rapoport BL
    Curr Med Res Opin; 2014 Sep; 30(9):1875-81. PubMed ID: 24911369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy.
    Warr DG; Street JC; Carides AD
    Support Care Cancer; 2011 Jun; 19(6):807-13. PubMed ID: 20461438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial.
    Xiong J; Zhao G; Yang S; Chen J
    Adv Ther; 2019 Feb; 36(2):355-364. PubMed ID: 30607545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
    Herrstedt J
    Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations.
    Rapoport BL; Aapro M; Chasen MR; Jordan K; Navari RM; Schnadig I; Schwartzberg L
    Drug Des Devel Ther; 2017; 11():2621-2629. PubMed ID: 28919712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK
    Bošnjak SM; Gralla RJ; Schwartzberg L
    Support Care Cancer; 2017 May; 25(5):1661-1671. PubMed ID: 28108820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiemetic care for patients with breast cancer: focus on drug interactions and safety concerns.
    Georgy A; Neceskas J; Goodin S
    Am J Health Syst Pharm; 2007 Nov; 64(21):2227-36. PubMed ID: 17959573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients.
    Yeo W; Lau TK; Li L; Lai KT; Pang E; Cheung M; Chan VT; Wong A; Soo WM; Yeung VT; Tse T; Lam DC; Yeung EW; Ng KP; Tang NL; Tong M; Suen JJ; Mo FK
    Breast; 2020 Apr; 50():30-38. PubMed ID: 31978815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aprepitant and fosaprepitant drug interactions: a systematic review.
    Patel P; Leeder JS; Piquette-Miller M; Dupuis LL
    Br J Clin Pharmacol; 2017 Oct; 83(10):2148-2162. PubMed ID: 28470980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.